Publications by authors named "Adrian Wiestner"

100Publications

Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.

J Clin Oncol 2020 Oct 7:JCO2000979. Epub 2020 Oct 7.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.00979DOI Listing
October 2020

Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.

Leuk Lymphoma 2020 Aug 5:1-11. Epub 2020 Aug 5.

Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1797007DOI Listing
August 2020

Ibrutinib for Chronic Lymphocytic Leukemia with Alterations.

N Engl J Med 2020 07;383(5):498-500

National Heart, Lung, and Blood Institute, Bethesda, MD

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc2005943DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456330PMC
July 2020

Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.

Leuk Lymphoma 2020 Oct 6;61(10):2375-2382. Epub 2020 Jun 6.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2020.1772477DOI Listing
October 2020

Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis.

J Clin Invest 2020 Apr;130(4):1793-1807

Mucosal Immunity Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI128322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108929PMC
April 2020

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.

Int J Mol Sci 2019 Dec 20;21(1). Epub 2019 Dec 20.

Laboratory of Lymphoid Malignancies, Hematology Branch, NHLBI, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms21010068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981459PMC
December 2019

IKAP-Identifying K mAjor cell Population groups in single-cell RNA-sequencing analysis.

Gigascience 2019 10;8(10)

Bioinformatics and Computational Biology Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, 12 South Drive, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/gigascience/giz121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771546PMC
October 2019

Six-packed antibodies punch better.

Haematologica 2019 09;104(9):1696-1699

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.224196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717577PMC
September 2019

Ibrutinib and Venetoclax - Doubling Down on CLL.

Authors:
Adrian Wiestner

N Engl J Med 2019 05;380(22):2169-2171

From the Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1904362DOI Listing
May 2019

Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Blood 2019 05 27;133(22):2452-2455. Epub 2019 Mar 27.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019896688DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543520PMC
May 2019

Protracted course of disseminated adenovirus disease with necrotizing granulomas in the liver.

Diagn Microbiol Infect Dis 2019 Jun 2;94(2):180-182. Epub 2019 Jan 2.

Division of Infectious Diseases, Mayo Clinic Hospital, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diagmicrobio.2018.12.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513271PMC
June 2019

TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Cancer Res 2019 01 29;79(2):360-371. Epub 2018 Nov 29.

Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-0781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342512PMC
January 2019

Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Leuk Lymphoma 2019 02 6;60(2):519-522. Epub 2018 Jul 6.

a Hematology Branch , National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1480775DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600815PMC
February 2019

Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.

Proc Natl Acad Sci U S A 2018 06 29;115(24):E5467-E5476. Epub 2018 May 29.

Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL 33458;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1719905115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004433PMC
June 2018

Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Leuk Lymphoma 2018 12 15;59(12):2792-2800. Epub 2018 May 15.

a Hematology Branch , National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1457147DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237652PMC
December 2018

Polyreactive antibodies in CLL correlate with the level of immunoglobulins not the number of B lymphocytes.

Leuk Lymphoma 2019 01 9;60(1):242-245. Epub 2018 May 9.

a Experimental Medicine Section, Laboratory of Sensory Biology , National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1464159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226347PMC
January 2019

Targeting B cell receptor signalling in cancer: preclinical and clinical advances.

Nat Rev Cancer 2018 03 19;18(3):148-167. Epub 2018 Jan 19.

Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.121DOI Listing
March 2018

CLL kinetics in the tumor microenvironment.

Oncotarget 2017 Oct 3;8(49):84634. Epub 2017 Oct 3.

Clare Sun: Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689558PMC
October 2017

Pneumocystis jirovecii Pneumonia in a Treatment-Naive Patient With Chronic Lymphocytic Leukemia.

Infect Dis Clin Pract (Baltim Md) 2016 Nov;24(6):e86-e87

Laboratory of Clinical Infectious Disease, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00019048-201611000-0003
Publisher Site
http://dx.doi.org/10.1097/IPC.0000000000000453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126642PMC
November 2016

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.

JAMA Oncol 2016 Dec;2(12):1656-1657

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2437DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421570PMC
December 2016

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Blood 2016 10 8;128(15):1940-1943. Epub 2016 Aug 8.

Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-06-722991DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064717PMC
October 2016

Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Reply.

Clin Cancer Res 2016 07;22(13):3412

Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0605DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933317PMC
July 2016

Choosing frontline chemoimmunotherapy for CLL.

Authors:
Adrian Wiestner

Lancet Oncol 2016 07 20;17(7):852-854. Epub 2016 May 20.

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(16)30118-8DOI Listing
July 2016

Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Semin Oncol 2016 Apr 8;43(2):222-32. Epub 2016 Feb 8.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856050PMC
April 2016

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.

JAMA Dermatol 2016 06;152(6):698-701

Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2016.0225DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415534PMC
June 2016

Under the microscope: CCL3 and T cells in the microenvironment of chronic lymphocytic leukemia.

Leuk Lymphoma 2016 23;57(3):501-2. Epub 2015 Dec 23.

a Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health , Bethesda , MD , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1085979DOI Listing
August 2016

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:
Adrian Wiestner

Haematologica 2015 Dec;100(12):1495-507

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.119123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666325PMC
December 2015

PROLONGing remissions in patients with CLL.

Authors:
Adrian Wiestner

Lancet Oncol 2015 Oct 13;16(13):1282-4. Epub 2015 Sep 13.

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20817, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00219-3DOI Listing
October 2015

Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.

Clin Cancer Res 2015 Oct 18;21(20):4642-51. Epub 2015 Jun 18.

Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609275PMC
October 2015

Nomenclature of Toso, Fas apoptosis inhibitory molecule 3, and IgM FcR.

J Immunol 2015 May;194(9):4055-7

Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1500222DOI Listing
May 2015

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.

Oncotarget 2015 Sep;6(29):27332-42

Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.2903DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694993PMC
September 2015

BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.

Authors:
Adrian Wiestner

Hematology Am Soc Hematol Educ Program 2014 Dec 18;2014(1):125-34. Epub 2014 Nov 18.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2014.1.125DOI Listing
December 2014

Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cancer Treat Res 2015 ;165:147-75

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bld 10, CRC 3-5140, 10 Center Drive, Bethesda, MD, 20892-1202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-13150-4_6DOI Listing
April 2015

Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.

Cancer Res 2014 Dec 24;74(24):7510-7520. Epub 2014 Oct 24.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268434PMC
December 2014

Chronic lymphocytic leukemia: moving forward-rapidly.

Semin Hematol 2014 Jul 2;51(3):157. Epub 2014 Jun 2.

National Heart, Lung and Blood Institute National Institutes of Health, Bethesda, MD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2014.05.009DOI Listing
July 2014

Do mantle cell lymphomas have an 'Achilles heel'?

Curr Opin Hematol 2014 Jul;21(4):350-7

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOH.0000000000000057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144918PMC
July 2014

Predicting treatment outcomes in CLL.

Authors:
Adrian Wiestner

Blood 2014 May;123(21):3212-4

NATIONAL INSTITUTES OF HEALTH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2014-04-565325DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046433PMC
May 2014

Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia.

Cancer Res 2014 May 5;74(9):2520-32. Epub 2014 Mar 5.

Authors' Affiliations: Houston Methodist Research Institute; The University of Texas M.D. Anderson Cancer Center, Houston, Texas; Hematology Branch, National Heart Lung and Blood Institute (NHLBI); National Center for Advancing Translational Sciences, NIH, Bethesda, Maryland; The University of Kansas Medical Center; Institute for Advancing Medical Innovation, Kansas University, Kansas City, Kansas; Division of Hematology, Department of Internal Medicine, The Comprehensive Cancer Center at the Ohio State University, Columbus, Ohio; and Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172421PMC
May 2014

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Cancer Discov 2014 Apr 3;4(4):480-93. Epub 2014 Feb 3.

1Lymphoid Malignancies Branch, 2Laboratory of Pathology, 3Experimental Immunology Branch, Center for Cancer Research; 4Biometric Research Branch, DCTD, National Cancer Institute; 5Hematology Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; 6Department of Pathology, University of Arizona, Tucson, Arizona; 7Oregon Health and Science University, Portland, Oregon; 8Cleveland Clinic Pathology and Laboratory Medicine Institute, Cleveland, Ohio; 9Department of Pathology, City of Hope National Medical Center, Duarte, California; 10Departments of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska; 11Department of Pathology, University of Würzburg, Würzburg; 12Department of Clinical Pathology, Robert-Bosch-Krankenhaus; 13Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany; 14British Columbia Cancer Agency, Vancouver, British Columbia, Canada; 15Hospital Clinic, University of Barcelona, Barcelona, Spain; 16Pathology Clinic, 17Institute for Cancer Research, Rikshospitalet University Hospital; 18Center for Cancer Biomedicine, Faculty Division of the Norwegian Radium Hospital, University of Oslo, Oslo, Norway; and 19Department of Molecular and Cellular Physiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0915DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992927PMC
April 2014

Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs.

PLoS One 2013 20;8(9):e75252. Epub 2013 Sep 20.

National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075252PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779154PMC
May 2014

B-cell receptor signaling as a driver of lymphoma development and evolution.

Semin Cancer Biol 2013 Dec 20;23(6):410-21. Epub 2013 Sep 20.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2013.09.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208312PMC
December 2013

Towards targeted therapy of chronic lymphocytic leukemia.

Adv Exp Med Biol 2013 ;792:259-91

Hematology Branch, National Heart, Lung, Blood Institute, National Institutes of Health, Bldg. 10, CRC 3-5140, 10 Center Drive, Bethesda, MD, 20892-1202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4614-8051-8_12DOI Listing
February 2014

Clinical use of BTK inhibitors.

Authors:
Adrian Wiestner

Clin Adv Hematol Oncol 2013 Aug;11 Suppl 9(8):10-2

National Heart, Lung, and Blood Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
August 2013

Clinical trial data on the BTK pathway in B-cell malignancies.

Authors:
Adrian Wiestner

Clin Adv Hematol Oncol 2013 Aug;11 Suppl 9(8):6-10

National Heart, Lung, and Blood Institute, Bethesda, MD.

View Article

Download full-text PDF

Source
August 2013

Bcl-2 level as a biomarker for 13q14 deletion in CLL.

Cytometry B Clin Cytom 2013 Jul-Aug;84(4):237-47. Epub 2013 May 14.

Center for Biologics Evaluation and Research, FDA, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963274PMC
February 2014

Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Hematol Oncol Clin North Am 2013 Apr;27(2):173-206

Hematology Institute, Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.01.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660068PMC
April 2013

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:
Adrian Wiestner

Hematology Am Soc Hematol Educ Program 2012 ;2012:88-96

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD20892-1202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2012.1.88DOI Listing
June 2013

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Mediterr J Hematol Infect Dis 2012 9;4(1):e2012067. Epub 2012 Oct 9.

Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Campus "A. Buzzati-Traverso", Rome, 00016, Italy.

View Article

Download full-text PDF

Source
http://www.mjhid.org/index.php/mjhid/article/view/2012.067
Publisher Site
http://dx.doi.org/10.4084/MJHID.2012.067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499997PMC
November 2012

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?

Oncoimmunology 2012 Sep;1(6):959-961

Department of Biochemistry and Molecular Genetics; University of Virginia School of Medicine; Charlottesville, VA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.20368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489759PMC
September 2012

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

Authors:
Adrian Wiestner

J Clin Oncol 2013 Jan 8;31(1):128-30. Epub 2012 Oct 8.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.4281DOI Listing
January 2013

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Authors:
Adrian Wiestner

Blood 2012 Dec 8;120(24):4684-91. Epub 2012 Aug 8.

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-05-423194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520616PMC
December 2012

Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.

J Clin Oncol 2012 Aug 9;30(23):2820-2. Epub 2012 Jul 9.

Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.43.3748DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3410400PMC
August 2012

Targeting malignant B cells with an immunotoxin against ROR1.

MAbs 2012 May-Jun;4(3):349-61. Epub 2012 Apr 26.

Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/mabs.19870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355487PMC
February 2013

Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia.

Mod Pathol 2012 Feb 18;25(2):246-59. Epub 2011 Nov 18.

Center for Human Immunology, Autoimmunity and Inflammation, National Heart Lung and Blood Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2011.164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512204PMC
February 2012